The Claim
In orbital fibroblasts from patients with severe Graves' ophthalmopathy, immunoglobulins from individuals with Graves' disease induce greater hyaluronan synthesis than recombinant human TSH, despite eliciting weaker cyclic AMP signaling.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In cells from the eye tissue of people with severe Graves' ophthalmopathy, antibodies from Graves' disease patients cause more hyaluronan production than thyroid-stimulating hormone, even though they activate a key signaling pathway less strongly.
See the scientific wording
In orbital fibroblasts from patients with severe Graves' ophthalmopathy, Graves' disease immunoglobulins induce hyaluronan synthesis more consistently than recombinant human TSH, despite weaker activation of cyclic AMP signaling, suggesting that autoantibodies trigger pathological tissue changes through mechanisms distinct from physiological thyroid stimulation.
Antibodies from people with Graves' disease bind to a receptor on fat cells behind the eye, activating a pathway that does not use the typical cellular signal called cAMP. This alternative pathway turns on a gene that makes a swelling substance called hyaluronan, which builds up and causes the eye to bulge.
What the research says
1 studyIn people with severe Graves' eye disease, immune antibodies make eye fat swell more reliably than the thyroid hormone does — even though the antibodies don’t turn on the usual cellular alarm as strongly. This means the antibodies must be using a different, hidden way to cause swelling.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.